Relapse And/or Refractory AML

1

Review clinical trials related to Relapse And/or Refractory AML. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Effect of Donor Chose on the Outcomes of GVHD Prophylaxis Underwent the Combined Treatment of ATG/PTCy for Haplo-HSCT

This is a prospective, multicenter, cohort study. The high-risk, relapse and refractory AML patients were enrolled in this study. And the goal of this study is to study the effect of the parous female donor and young male donor on the outcomes of graft-versus-host disease (GVHD) prophylaxis underwent the combination of ATG and PTCy for haploidentical peripheral blood stem cell transplantation

Participants needed: 114
Trial details
Age: 18-55Biological sex: AllType: ObservationalSponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineUpdated: Jan 7, 2025Duration: 1 Year
Eligibility criteria

ELN prognostic stratification high-risk group (see Appendix for criteria) [+3]

Intermediate-low risk AML patients (ELN criteria); [+3]